RxDoctor Payments Data

Naser Azar, MD

Family Medicine · Corona, CANPI 1700956331

Payments from drug & device makers

$3,090in general payments, 2019–2025

Across 179 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$557
  • AstraZeneca$465
  • Novo Nordisk$426
  • Lilly USA, LLC$363
  • Redhill Biopharma Inc.$238
  • Merck$152
  • plus $889 from 21 others

What the payments were for

  • Food & beverage$3,083100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,090 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$76,638
Medicare patients
363
Services billed
1,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter113$133,662
OzempicSemaglutide76$103,551
JardianceEmpagliflozin77$100,281
JanuviaSitagliptin Phosphate59$71,075
EliquisApixaban53$54,303
TrulicityDulaglutide36$53,159
Bydureon BciseExenatide Microspheres14$21,303
XareltoRivaroxaban18$19,544
FarxigaDapagliflozin Propanediol12$15,929
Metoprolol Succinate534$11,967
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$11,939
Rosuvastatin Calcium312$6,432
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,347
Vitamin D2Ergocalciferol (Vitamin D2)366$4,034
BreynaBudesonide/Formoterol Fumarate11$3,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$557$133,662113 claims
Novo NordiskOzempic$426$103,55176 claims
MerckJanuvia$152$71,07559 claims
PfizerEliquis$89$54,30353 claims
Lilly USA, LLCTrulicity$363$53,15936 claims
Johnson & JohnsonXarelto$15$19,54418 claims
AstraZenecaFarxiga$465$15,92912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →